BC Extra | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
BC Innovations | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
BC Innovations | Nov 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
BC Innovations | May 8, 2017
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
BioCentury | Dec 15, 2014
Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc. 's novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics....
BC Week In Review | Mar 24, 2014
Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...
BC Week In Review | Apr 18, 2011
Clinical News

IMO-3100: Phase I data

A placebo-controlled, multiple-dose Phase I trial in 24 healthy volunteers showed that once-weekly 0.64 mg/kg and twice-weekly 0.32 mg/kg subcutaneous IMO-3100 for 4 weeks were well tolerated with no serious adverse events reported. Additionally, IMO-3100...
BioCentury | Jan 17, 2011
Emerging Company Profile

Inagen: Defense creates offense

The use of immunotoxins to target and kill specific cells has largely been limited to the field of cancer, but Inagen ApS hopes to use a similar approach to target and kill cytomegalovirus-infected cells. Because...
BC Week In Review | Oct 11, 2010
Clinical News

SCV-07: Additional Phase IIa data

A gene expression analysis of RNA samples from 59 head and neck cancer patients receiving chemotherapy in a double-blind, dose-ranging, U.S. Phase IIa trial showed that patients receiving 0.1 mg/kg SCV-07 had significantly higher levels...
BioCentury | Sep 27, 2010
Product Development

Betting on a pair of JAKs

With INCB18424 , Incyte Corp. and partner Novartis AG are tackling a first-in-class compound in an indication with no approved therapies, but where the mechanism is murky and the regulatory requirements aren't uniform. This month's publication...
Items per page:
1 - 10 of 17